Last reviewed · How we verify
anti-arrhythmic drug therapy
At a glance
| Generic name | anti-arrhythmic drug therapy |
|---|---|
| Also known as | sotalol, flecainide, propafenone, dronedarone |
| Sponsor | Biosense Webster EMEA |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- All other events < 5% Freq
- Atrial fibrillation
- Atrial Fibrillation
- Palpitations
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |